RT Journal Article
SR Electronic
T1 “TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia”
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 232280
DO 10.1101/232280
A1 Kevin G. Burfeind
A1 Xinxia Zhu
A1 Peter R. Levasseur
A1 Katherine A. Michaelis
A1 Mason A. Norgard
A1 Daniel L. Marks
YR 2017
UL http://biorxiv.org/content/early/2017/12/11/232280.abstract
AB Hypothalamic inflammation is a key component of acute sickness behavior and cachexia, yet mechanisms of inflammatory signaling in the central nervous system remain unclear. We assessed the role of TRIF signaling in acute inflammation (lipopolysaccharide (LPS) challenge) and in a chronic inflammatory state (cancer cachexia). TRIFKO mice resisted anorexia and weight loss after peripheral (intraperitoneal, IP) or central (intracerebroventricular, ICV) LPS challenge and in a model of pancreatic cancer cachexia. Compared to WT mice, TRIFKO mice showed attenuated upregulation of Il6, Ccl2, Ccl5, Cxcl1, Cxcl2, and Cxcl10 in the hypothalamus after IP LPS treatment, as well as attenuated microglial activation and neutrophil infiltration into the brain after ICV LPS treatment. Our results show that TRIF is an important inflammatory signaling mediator of sickness behavior and cachexia and presents a novel therapeutic target for these conditions.